ET and Diabetic Nephropathy: Preclinical and Clinical Studies

Elena Gagliardini, Carlamaria Zoja, Ariela Benigni

Research output: Contribution to journalArticlepeer-review


The incidence of progressive kidney disease associated with diabetes continues to increase worldwide. Only partial renoprotection is achieved by current standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers, increasing the need for novel therapeutic approaches. Experimental studies have provided evidence of a pathogenic role for endothelin-1 (ET-1) and its cognate receptors in the development and progression of diabetic nephropathy. ET-1, mainly through the activation of ETA receptor, contributes to renal cell injury, inflammation, and fibrosis. In animal models of type 1 and type 2 diabetes, ETA-selective antagonists have been shown to provide renoprotective effects, supplying the rationale for clinical trials in patients with diabetic nephropathy with ETA-receptor antagonists administered in addition to renin-angiotensin system blockade.

Original languageEnglish
Pages (from-to)188-196
Number of pages9
JournalSeminars in Nephrology
Issue number2
Publication statusPublished - Mar 1 2015


  • Diabetic nephropathy
  • Dual inhibition of endothelin-converting enzyme
  • Endothelin-receptor antagonists
  • Neutral endopeptidase
  • Renin-angiotensin system inhibitors

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)


Dive into the research topics of 'ET and Diabetic Nephropathy: Preclinical and Clinical Studies'. Together they form a unique fingerprint.

Cite this